share_log
Reuters ·  May 1 08:35
Sellas Life Sciences: Study Enrollment Ongoing at 30Mg Biw Dose of Sls009 With Expansion Cohort of Asxl1 Mutation Patients; Updates Expected in Q3
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment